Brazilian biotechnology startup BioLinker has successfully secured $1.7 million in a new funding round to accelerate its innovative work in synthetic biology, recombinant protein manufacturing, and artificial intelligence infrastructure. The fresh capital infusion marks a significant milestone for the company, which was founded in 2018 by a group of forward-thinking scientists hailing from the University of São Paulo. The investment round was spearheaded by Axcell, which contributed a substantial $1.4 million, while the São Paulo Research Foundation, known as FAPESP, added approximately $240,000 through its highly competitive PIPE Phase 2 program.
The successful completion of this funding phase provides BioLinker with the financial runway necessary to pursue its ambitious operational roadmap. Notably, the investment round remains open as the company actively seeks to bring an international strategic investor on board. This ongoing search is part of a broader expansion strategy designed to solidify BioLinker’s market position ahead of a planned Series A funding round anticipated within the next two years. Operating on a solid foundation of recurring revenue, BioLinker projects that the newly secured capital will comfortably fund three full years of continued operations, research, and development.
Founded on the principles of cutting-edge genetic engineering, BioLinker specializes in the development and manufacture of high-quality recombinant proteins. These specialized biological products play a critical foundational role across a wide array of sectors, including academic and commercial research, advanced medical and biological diagnostics, and diverse industrial applications. By harnessing the power of synthetic biology, the startup has positioned itself at the forefront of Brazil’s evolving biotech landscape, providing essential tools and components that empower researchers and industrial partners to push the boundaries of modern science.
With the newly acquired funds, BioLinker is preparing to embark on a major infrastructure expansion by building a state-of-the-art, automated laboratory. This cutting-edge facility will be strategically located at the Amazon BioBusiness Center situated in Manaus, positioning the company within one of the world’s most biodiverse and symbolically relevant regions for environmental and biological research. The new laboratory will leverage advanced robotics and automation to generate vast quantities of biological data at scale. This data-generation capability is critical for BioLinker’s next wave of technological development, as it will be directly utilized to train sophisticated artificial intelligence models while simultaneously expanding the industrial capacity for DNA production within Brazil.
The establishment of the automated facility in Manaus is also expected to have a profound impact on the company’s organizational capacity and talent acquisition efforts. To support the operational demands of the new laboratory and its expanding technology initiatives, BioLinker plans to double its current workforce. The company will grow its team from 12 employees to 24, bringing on board skilled professionals in fields ranging from biotechnology and robotics to artificial intelligence and data science. This workforce expansion underscores BioLinker’s commitment to nurturing local scientific talent and fostering high-tech employment opportunities within the region.
The ongoing backing from established institutions like FAPESP through its PIPE Phase 2 program highlights the consistent confidence that the Brazilian scientific and financial establishment places in BioLinker’s business model and technological vision. Programs designed to foster innovative research and development in small businesses have long served as a vital springboard for Brazil’s emerging technology sector, helping bridge the gap between academic research and commercialization. By pairing public research support with substantial private venture investment from firms like Axcell, BioLinker has built a robust financial structure capable of sustaining long-term innovation.
As BioLinker looks toward the horizon, the convergence of synthetic biology, automation, and artificial intelligence represents a transformative frontier for the life sciences industry in Latin America. By combining the rich biological context of the Amazon with world-class computational and robotic infrastructure, the startup is carving out a unique niche that bridges ecological biodiversity with digital-age innovation. With its current funding secured, operations mapped out for the next three years, and international partnerships actively under negotiation, BioLinker is well-positioned to execute its strategic vision and pave the way for its upcoming Series A milestone.
